Harmony Biosciences Holdings Inc. (HRMY): Price and Financial Metrics
GET POWR RATINGS... FREE!
HRMY Stock Price Chart Interactive Chart >
HRMY Price/Volume Stats
| Current price | $38.16 | 52-week high | $52.74 |
| Prev. close | $37.64 | 52-week low | $25.09 |
| Day low | $37.44 | Volume | 306,800 |
| Day high | $38.44 | Avg. volume | 236,939 |
| 50-day MA | $32.56 | Dividend yield | N/A |
| 200-day MA | $32.73 | Market Cap | 2.18B |
Harmony Biosciences Holdings Inc. (HRMY) Company Bio
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Latest HRMY News From Around the Web
Below are the latest news stories about Harmony Biosciences Holdings Inc that investors may wish to consider to help them evaluate HRMY as an investment opportunity.
Harmony Biosciences Announces Winners of Patients at the Heart and Progress at the Heart on Third Annual World Narcolepsy DayHarmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced winners of the Patient at the Heart and Progress at the Heart programs in honor of the third annual World Narcolepsy Day. |
President And CEO Of Harmony Biosciences Trades $1.10 Million In Company StockJohn Jacobs , President And CEO at Harmony Biosciences (NASDAQ: HRMY ), made a large buy and sell of company shares on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that John Jacobs purchased 25,000 Harmony Biosciences shares at a price of $8.22 per share for a total of $205,500 on September 13. They then sold their shares on the same day in the open market. They sold at a price of $35.93 to raise a total of $898,262 from the stock sale. This transaction has resulted in Jacobs no longer owning shares of the company. Harmony Biosciences Full story available on Benzinga.com |
Notable Harmony Biosciences Insider Trades $457.98 Thousand In Company StockJeffrey Dayno, Chief Medical Officer at Harmony Biosciences (NASDAQ:HRMY), made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 7, Jeffrey Dayno bought 10,000 Harmony Biosciences shares at a price of $8.22 per share, for a total of $82,200. They then sold their shares on the same day in the open market at a price of $37.58 to raise a total of $375,783 fr |
Harmony Biosciences Holdings Inc (HRMY): Price Now Near $38.26; Daily Chart Shows An Uptrend on 20 Day BasisThis is a reversal of the price action on the previous hour, in which price moved up. The post Harmony Biosciences Holdings Inc (HRMY): Price Now Near $38.26; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News . |
Harmony Biosciences Holdings Inc (HRMY): Price Up $0.53 (1.55)% Over Past Day, Up $0.11 (0.33)% Over Past HourIt''s been a feast for bulls operating on the daily timeframe, as hrmy has now gone up 4 of the past 5 days. The post Harmony Biosciences Holdings Inc (HRMY): Price Up $0.53 (1.55)% Over Past Day, Up $0.11 (0.33)% Over Past Hour appeared first on ETF Daily News . |
HRMY Price Returns
| 1-mo | 8.19% |
| 3-mo | 31.18% |
| 6-mo | 15.50% |
| 1-year | 12.87% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 5.56% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...